Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of RC010 Inhalation Powder in Healthy Chinese Participants
NCT07528703Phase 1Not yet recruiting
- Sponsor
- Reju Therapeutics
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing RC010 Inhalation Powder with RC010 Inhalation Powder placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events, Serious Adverse Events and 3 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
RC010
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07528703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07528703.